Oxford Biomedica PLC MHRA Licence For Commercial Supply
August 07 2017 - 1:00AM
RNS Non-Regulatory
TIDMOXB
Oxford Biomedica PLC
07 August 2017
Oxford BioMedica Announces MHRA Licence For Commercial
Supply
London, UK - 07 August 2017: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE:OXB), a leading gene and cell
therapy group, today announces that it has been granted a
Manufacturer/Importer License (MIA), from the UK Medicines and
Healthcare products Regulatory Agency ("MHRA"), to manufacture and
distribute lentiviral vector material for commercial supply. This
is in addition to the existing MIA (IMP) licence for
Investigational Medicinal Products (IMPs) manufacture, which the
Group has held for over 10 years.
Including significant know-how and proprietary analytical
methods, Oxford BioMedica has established a world-leading platform
for lentiviral vector bioprocessing at its state-of-the-art
custom-built facilities in Oxford, UK, that allow full control over
the entire lentiviral vector manufacturing process.
Oxford BioMedica recently signed an agreement with Novartis for
the commercial and clinical supply of lentiviral vectors used to
generate CTL019 and other undisclosed CAR-T products, for which
Oxford BioMedica could potentially receive in excess of $100m from
Novartis over the next three years.
In addition to the Novartis agreement, Oxford BioMedica has
bioprocessing and process development partnerships with Immune
Design and Orchard Therapeutics.
John Dawson, Chief Executive Officer of Oxford BioMedica,
commented: "Receiving regulatory approval for the manufacture of
lentiviral vector material for commercial supply is another
significant milestone for Oxford BioMedica. We look forward to
working closely with our existing partners in lentiviral vector
bioprocessing and process development, and believe that our
expertise and technology will be of benefit to other companies
working in gene and cell therapy."
- Ends -
For further information, please
contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive Officer 783 000
Tim Watts, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0)20
Mary-Jane Elliott/Matthew Neal/Philippa 3709 5700
Gardner/Laura Thornton
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, Orchard
Therapeutics and Immune Design, through which it has long-term
economic interests in other potential gene and cell therapy
products. Oxford BioMedica is based across several locations in
Oxfordshire, UK and employs more than 250 people. Further
information is available at www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFESTSISIID
(END) Dow Jones Newswires
August 07, 2017 02:00 ET (06:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024